PUT/NOVO-NORDISK B/400/2/21.06.24 | Market Closed - BOERSE MUENCHEN 19:25:30 31/05/2024 BST | ||
| 0.024 EUR | -25.00% |
|
| 1 month | -61.29% | ||
| 3 months | -89.92% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 0.024 | -25.00% |
| 30/05/24 | 0.032 | -13.51% |
| 29/05/24 | 0.037 | +2.78% |
| 28/05/24 | 0.036 | -32.08% |
| 27/05/24 | 0.053 | -5.36% |
Real-time BOERSE MUENCHEN
Last update May 31, 2024 at 07:25 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| WKN | GP5QRQ |
| ISIN | DE000GP5QRQ9 |
| Date issued | 12/06/2023 |
| Strike | 400 kr |
| Maturity | 21/06/2024 (20 Days) |
| Parity | 0.5 : 1 |
| Emission price | 2.94 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.21 € |
|---|---|
| Lowest since issue | 0.003 € |
| Spread | 3 € |
| Spread % | 99.34% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Warrants
- Warrant
